Our Lady of Bellefonte Hospital INC
Our Lady of Bellefonte Hospital INC was paid $12.13M by Medicaid between Jan 2018 and Apr 2020, across 280 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 6.5% of everything it billed.
ASHLAND, KY 41101
Next to other General Acute Care Hospital providers in Kentucky
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 190,660 | $6.01M | |
| 2019 | 169,283 | $5.10M | |
| 2020 | 31,695 | $1.01M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 6.5% | 1,825 | 1,667 | $790K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.0% | 7,712 | 6,589 | $722K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.8% | 2,635 | 1,785 | $698K |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.9% | 738 | 549 | $599K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.8% | 5,316 | 4,523 | $576K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.5% | 2,730 | 2,173 | $425K |
| 80050 | General health panel | 2.4% | 7,527 | 6,875 | $292K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 804 | 600 | $269K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 2,141 | 1,563 | $247K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.9% | 763 | 683 | $236K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.6% | 769 | 379 | $191K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 2,289 | 1,112 | $182K |
268 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 6,635 | $179K |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 1.4% | 1,040 | $172K |
| 80053 | Comprehensive metabolic panel | 1.4% | 28,593 | $168K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 758 | $165K |
| 0100U | 1.4% | 384 | $164K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 7,480 | $160K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 21,614 | $155K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 3,012 | $144K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.0% | 2,142 | $126K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 2,525 | $125K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.0% | 1,873 | $124K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,268 | $118K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,099 | $114K |
| 99218 | <1% | 2,360 | $107K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,679 | $106K |
| 80061 | Lipid panel | <1% | 7,851 | $100K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,140 | $99K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 716 | $89K |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,014 | $89K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,385 | $89K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,938 | $87K |
| 93017 | <1% | 471 | $82K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,450 | $80K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,117 | $79K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,936 | $77K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,743 | $75K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,029 | $74K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 329 | $71K |
| 87581 | <1% | 1,829 | $67K | |
| 87486 | <1% | 2,023 | $67K | |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 407 | $63K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 291 | $63K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,513 | $62K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,524 | $61K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,111 | $61K |
| 80074 | <1% | 1,278 | $60K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 277 | $57K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,590 | $54K |
| 87902 | <1% | 198 | $54K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 911 | $53K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,131 | $52K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 361 | $51K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 173 | $51K |
| 71250 | <1% | 344 | $50K | |
| 0099U | <1% | 346 | $49K | |
| 73630 | <1% | 981 | $48K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,519 | $46K |
| 82607 | <1% | 3,186 | $45K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,852 | $44K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,033 | $44K |
| 84484 | <1% | 3,675 | $42K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,778 | $41K |
| 96376 | <1% | 1,161 | $41K | |
| 87070 | <1% | 4,238 | $41K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 283 | $40K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,695 | $40K |
| 76536 | <1% | 318 | $39K | |
| 74019 | <1% | 529 | $36K | |
| 84703 | <1% | 3,268 | $35K | |
| 84436 | <1% | 5,193 | $35K | |
| 84479 | <1% | 5,028 | $35K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 135 | $34K |
| 95886 | <1% | 365 | $33K | |
| 93971 | <1% | 339 | $33K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,287 | $33K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 689 | $32K |
| 81001 | <1% | 6,321 | $32K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 792 | $31K |
| 87522 | Neg quan hep c or qual rna | <1% | 692 | $30K |
| 86480 | <1% | 757 | $29K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,587 | $28K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 159 | $28K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 70 | $28K |
| 73130 | <1% | 542 | $26K | |
| 83880 | <1% | 994 | $26K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,764 | $25K |
| 72100 | <1% | 435 | $25K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 45 | $25K |
| 73564 | <1% | 437 | $25K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 384 | $25K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,377 | $25K |
| 88142 | <1% | 1,316 | $24K | |
| 88304 | <1% | 555 | $24K | |
| 73030 | <1% | 504 | $24K | |
| 73610 | <1% | 459 | $24K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 806 | $23K |
| 83735 | <1% | 3,830 | $23K | |
| 97162 | <1% | 606 | $22K | |
| 76830 | Ultrasound, transvaginal | <1% | 178 | $22K |
| 00731 | <1% | 186 | $22K | |
| 83690 | <1% | 2,895 | $22K | |
| 87507 | <1% | 99 | $22K | |
| 95911 | <1% | 58 | $21K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,571 | $21K |
| 86665 | <1% | 561 | $21K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 29 | $20K |
| 84145 | <1% | 1,137 | $20K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 562 | $20K |
| 86140 | <1% | 3,458 | $19K | |
| 88312 | <1% | 594 | $19K | |
| 76642 | <1% | 189 | $19K | |
| 94729 | <1% | 349 | $19K | |
| 87040 | <1% | 1,918 | $19K | |
| 94727 | <1% | 334 | $18K | |
| 00840 | <1% | 50 | $18K | |
| 72110 | <1% | 245 | $18K | |
| 73221 | <1% | 85 | $18K | |
| 72141 | <1% | 105 | $17K | |
| 87186 | <1% | 1,849 | $17K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 595 | $16K |
| 86738 | <1% | 1,003 | $16K | |
| 84439 | <1% | 1,751 | $16K | |
| 83516 | <1% | 378 | $16K | |
| 84702 | <1% | 557 | $16K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 284 | $16K |
| 94060 | <1% | 186 | $16K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,215 | $15K |
| J3490 | Unclassified drugs | <1% | 1,302 | $15K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 46 | $14K |
| 83550 | <1% | 1,584 | $14K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,184 | $13K |
| 80076 | <1% | 1,584 | $13K | |
| 83605 | <1% | 1,379 | $13K | |
| 82652 | <1% | 465 | $13K | |
| 82728 | <1% | 1,013 | $13K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,792 | $13K |
| 84403 | <1% | 462 | $13K | |
| 84153 | <1% | 750 | $13K | |
| 87641 | <1% | 773 | $13K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 87 | $13K |
| 74018 | <1% | 292 | $12K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,004 | $12K |
| 95811 | <1% | 27 | $12K | |
| 97597 | <1% | 748 | $12K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 233 | $12K |
| 83540 | <1% | 1,782 | $11K | |
| 87088 | <1% | 1,411 | $11K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 633 | $11K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 93 | $11K |
| 85652 | <1% | 3,168 | $11K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,519 | $11K |
| 84402 | <1% | 392 | $11K | |
| 85610 | <1% | 2,750 | $10K | |
| 93226 | <1% | 58 | $10K | |
| 85379 | <1% | 806 | $10K | |
| 77080 | <1% | 311 | $10K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 517 | $10K |
| 73502 | <1% | 221 | $10K | |
| 87077 | <1% | 959 | $9K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 42 | $9K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 915 | $9K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,743 | $9K |
| 93225 | <1% | 95 | $9K | |
| 76770 | <1% | 56 | $9K | |
| 86664 | <1% | 573 | $9K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 486 | $9K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 301 | $9K |
| 82043 | <1% | 1,669 | $9K | |
| 86800 | <1% | 487 | $8K | |
| 85730 | <1% | 1,410 | $8K | |
| 82962 | <1% | 3,127 | $8K | |
| 82150 | <1% | 1,180 | $8K | |
| 82803 | <1% | 497 | $8K | |
| 82570 | <1% | 1,571 | $8K | |
| 94070 | <1% | 91 | $8K | |
| 73560 | <1% | 147 | $8K | |
| 83001 | <1% | 390 | $8K | |
| 86663 | <1% | 542 | $7K | |
| 85027 | <1% | 1,127 | $7K | |
| 82746 | <1% | 486 | $7K | |
| 86376 | <1% | 470 | $7K | |
| 84146 | <1% | 342 | $7K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,205 | $7K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 869 | $6K |
| 81025 | <1% | 701 | $6K | |
| G0378 | Hospital observation service, per hour | <1% | 171 | $6K |
| 81374 | <1% | 88 | $6K | |
| 87481 | <1% | 168 | $6K | |
| 72070 | <1% | 119 | $6K | |
| 73110 | <1% | 132 | $6K | |
| 86038 | <1% | 515 | $6K | |
| 00126 | <1% | 42 | $5K | |
| 81003 | <1% | 1,384 | $5K | |
| 86308 | <1% | 637 | $5K | |
| 00811 | <1% | 45 | $5K | |
| 72040 | <1% | 84 | $5K | |
| 86803 | <1% | 329 | $5K | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 128 | $5K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $4K |
| 87807 | <1% | 251 | $4K | |
| 88307 | <1% | 53 | $4K | |
| 36600 | <1% | 449 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 595 | $4K |
| 86850 | <1% | 566 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,240 | $4K |
| 86706 | <1% | 359 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 392 | $3K |
| 87340 | <1% | 315 | $3K | |
| 87205 | <1% | 770 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 261 | $3K |
| 84550 | <1% | 669 | $3K | |
| 86900 | <1% | 771 | $3K | |
| 0097U | <1% | 45 | $3K | |
| 90715 | <1% | 104 | $3K | |
| 83002 | <1% | 132 | $3K | |
| 86901 | <1% | 734 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 72 | $3K |
| 84100 | <1% | 560 | $3K | |
| 82947 | <1% | 666 | $2K | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 40 | $2K |
| 72050 | <1% | 29 | $2K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 48 | $2K |
| 86708 | <1% | 176 | $2K | |
| 86430 | <1% | 346 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 667 | $2K |
| 74241 | <1% | 15 | $2K | |
| C1769 | Guide wire | <1% | 47 | $2K |
| 82550 | <1% | 292 | $2K | |
| 86003 | <1% | 13 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 78 | $2K |
| 86677 | <1% | 80 | $2K | |
| 82784 | <1% | 478 | $2K | |
| 82627 | <1% | 84 | $2K | |
| 80164 | <1% | 124 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $1K |
| 86256 | <1% | 61 | $1K | |
| 86592 | <1% | 319 | $1K | |
| 83525 | <1% | 109 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 115 | $1K |
| 86704 | <1% | 102 | $1K | |
| 86804 | <1% | 74 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $1K |
| 87529 | <1% | 13 | $986.08 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 96 | $757.13 |
| 73080 | <1% | 14 | $751.19 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 669 | $728.20 |
| 86160 | <1% | 24 | $645.39 | |
| 73590 | <1% | 12 | $634.48 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 13 | $572.29 |
| 81596 | <1% | 32 | $512.00 | |
| 82172 | <1% | 30 | $506.22 | |
| 97161 | <1% | 19 | $490.67 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 13 | $485.35 |
| 85018 | <1% | 199 | $456.80 | |
| 82670 | <1% | 25 | $454.58 | |
| 83615 | <1% | 67 | $450.02 | |
| 83883 | <1% | 31 | $409.40 | |
| 87046 | <1% | 28 | $397.80 | |
| 85014 | <1% | 173 | $381.66 | |
| 83010 | <1% | 30 | $378.64 | |
| 82272 | <1% | 13 | $317.97 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 34 | $316.66 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 28 | $306.25 |
| 87045 | <1% | 28 | $210.76 | |
| 82553 | <1% | 17 | $195.10 | |
| J7674 | Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg | <1% | 15 | $170.55 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 359 | $142.78 |
| J0592 | Injection, buprenorphine hydrochloride, 0.1 mg | <1% | 16 | $136.43 |
| 86705 | <1% | 14 | $131.73 | |
| 86060 | <1% | 12 | $100.37 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 93 | $81.92 |
| 84132 | <1% | 14 | $75.06 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 30 | $61.89 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 40 | $49.02 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 253 | $40.01 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 20 | $16.23 |
| A9270 | Non-covered item or service | <1% | 482 | $1.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 92 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| The Chambersburg Hospital | Chambersburg, PA | $10.29M |
| Vna Home Health Services | York, PA | $3.99M |
| Waynesboro Hospital | Waynesboro, PA | $1.48M |
| Waynesboro Hospital | Fayetteville, PA | $831K |
| The Chambersburg Hospital | Chambersburg, PA | $801K |
| Wellspan Surgery and Rehabilitation Hospital | York, PA | $399K |
| Our Lady of Bellefonte Hospital INC | Ashland, KY | $200K |
| Waynesboro Hospital | Wayesboro, PA | $11K |
| The Chambersburg Hospital | Chambersburg, PA | $6K |
| The Chambersburg Hospital | Chambersburg, PA | $198.19 |
| Waynesboro Hospital | Waynesboro, PA | $6.58 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.